Recurrent Respiratory Papillomatosis Clinical Trial
Official title:
Phase I Safety and Tolerability Study of EF-022 in Adult Subjects With Recurrent Respiratory Papillomatosis
This study evaluates the safety and tolerability of the investigational drug EF-022 in the treatment of adult patients with Recurrent Respiratory Papillomatosis (RRP). Patients will be administered EF-022, either intramuscular or subcutaneous, for a period of 6 months. Preliminary effect of the drug on the disease will be evaluated by following the number and severity of the lesions in the respiratory tract and the effect on voice changes.
Status | Not yet recruiting |
Enrollment | 6 |
Est. completion date | |
Est. primary completion date | September 2018 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: 1. Patients with documented diagnosis of recurrent respiratory papillomatosis 2. Patients with measurable disease 3. Patients presenting at least one of the following severity criteria: Derkay score = 8 , Voice handicap index (VHI) =11 4. Adult male and female subjects, age of 18 and above (=18 yrs) 5. Patients with documentation on number of debulking procedures done during past 12 months 6. Estimated expectancy time for next debulking procedure must be at least 3 months. 7. Must be at least 4 weeks (>4 weeks) since last treatment including cytotoxic therapy, biological or immunotherapy, anti-viral therapy, molecularly targeted therapy or steroid treatment. 8. Must be at least 2 weeks (>2weeks) since last NSAID treatment. 9. Must have adequately recovered (to at least Grade 1 level) from adverse effects of prior therapies. 10. Female of child bearing potential must have a negative pregnancy test and must be practicing an effective method of birth control 11. Patients or their guardians must sign an informed consent indicating that they are aware of the investigational nature of this study Exclusion Criteria: 1. Patient on concurrent steroids or anti-inflammatory non steroid treatment. 2. Active autoimmune disease 3. Known major immunodeficiency 4. Known to be Positive for HIV, Hepatitis B surface antigen, Hepatitis C antibody 5. Have absolute neutrophil counts below 1.5X 10^9/L 6. Hemoglobin below 10.0 g/dL 7. White blood cell counts below 3.5X10^9/L. 8. Granulocytes below 1.5X10^9/L. 9. Have Platelets below 100 X 10^9/L 10. Abnormal renal function with creatinine above 1.5X the upper limit of normal (ULN) 11. Abnormal liver function tests with bilirubin above 1.5X the ULN, AST and ALT above 2.5 X ULN. 12. Patients with active cardiovascular disease under continuous treatment 13. Patients with associated malignancy currently receiving chemotherapy and/or radiation. 14. Female adult patients that are pregnant, nursing or plan to nurse during and up to 12 months of treatment period. 15. Subjects receiving another investigational drug. 16. Patients with concurrent or history of malignancy within 5 years. |
Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Efranat Ltd. |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | CTCAE v.4.03 criteria will constitute the primary safety endpoints to be monitored throughout this study | 6 months | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00747461 -
Interventional Cryotherapy for the Eradication of Benign Airway Disease ("ICE the BAD")
|
Phase 4 | |
Completed |
NCT01020747 -
Bevacizumab for Treatment of Recurrent Respiratory Papillomatosis (RRP)
|
Phase 1 | |
Completed |
NCT00038714 -
A Trial Study of SGN-00101 in Treating Pediatric Patients With Recurrent Respiratory Papillomatosis
|
Phase 2 | |
Completed |
NCT00205374 -
Use of Cidofovir for Recurrent Respiratory Papillomatosis
|
Phase 4 | |
Active, not recruiting |
NCT04724980 -
Adjuvant PRGN-2012 in Adult Patients With Recurrent Respiratory Papillomatosis
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT04645602 -
Lenvatinib and Pembrolizumab Combination Therapy In HPV-associated Recurrent Respiratory Papilloma Patients With Laryngeal, Tracheal, and/or Pulmonary Involvement
|
Phase 2 | |
Recruiting |
NCT01793168 -
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
|
||
Withdrawn |
NCT01058317 -
Propranolol Administration in Pediatric Patients With Recurrent Respiratory Papillomatosis
|
Phase 2/Phase 3 | |
Withdrawn |
NCT00829608 -
Therapeutic Treatment With Human Papillomavirus Quadrivalent Vaccine for Recurrent Respiratory Papillomatosis
|
Phase 0 | |
Completed |
NCT00550914 -
Multi-Center, Randomized Trial of the Pulsed Dye Laser for JORRP
|
N/A | |
Not yet recruiting |
NCT01995721 -
4-valent HPV Vaccine to Treat Recurrent Respiratory Papillomatosis in Children
|
Phase 3 | |
Completed |
NCT02217358 -
Value of Narrow Band Imaging (NBI) Endoscopy in the Early Diagnosis of Laryngeal Cancer and Precancerous Lesions
|
N/A | |
Completed |
NCT00571701 -
Study of Celebrex (Celecoxib) in Patients With Recurrent Respiratory Papillomatosis
|
Phase 2 | |
Recruiting |
NCT02555800 -
Bevacizumab Versus Cidofovir for the Treatment of Recurrent Respiratory Papillomatosis
|
Phase 2 | |
Completed |
NCT03707587 -
M7824 in People With Recurrent Respiratory Papillomatosis
|
Phase 2 | |
Completed |
NCT02859454 -
Avelumab for People With Recurrent Respiratory Papillomatosis
|
Phase 2 | |
Active, not recruiting |
NCT02632344 -
Pembrolizumab for HPV-associated Recurrent Respiratory Papilloma Patients
|
Phase 2 | |
Completed |
NCT02592902 -
Recurrent Respiratory Papillomatosis and Extraesophageal Reflux
|
N/A | |
Recruiting |
NCT06412172 -
The Natural History and Biological Study of Pulmonary Recurrent Respiratory Papillomatosis (pRRP)
|
||
Recruiting |
NCT03465280 -
Airway Intervention Registry (AIR): Recurrent Respiratory Papillomatosis (RRP)
|